Articles related to CLINICAL STUDY

In what is thought to be the largest study to date of any type of ketamine treatment, the findings revealed that, after four sessions, 89 percent of participants reported improvement in their depression and/or anxiety symptoms. On the PHQ-9 or GAD-7 scale, 63 percent of participants saw a 50% or greater improvement. PHQ-9 remission rates were 32.6 percent and GAD-7 remission rates were 31.3 percent. Furthermore, at the end of the four weeks, 62 percent of patients who had suicidal ideation prior to treatment reported no suicidal ideation.

Researchers studied the effects of four repeated low doses of LSD, administered under lab conditions every three to four days, using approximately 1/8th the dose typically used to “trip” on LSD.

Gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) AML but seldom reduces FLT3mut burden or induces sustained efficacy. This phase Ib open-label, dose-escalation/dose-expansion study enrolled 61 patients (63% having received prior FLT3 therapy) to receive 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure, but did require dose interruptions for myelosuppression.

A detailed summarization of the clinical presentation of 197 individuals with PCR-confirmed diagnosis of monkeypox in the UK. The summary documents a highly variable prodrome in terms of prodromal symptoms and timing to eruption of visible lesions. Systemic illness was seen in 86% of patients. After mucocutaneous lesions, seen in 100% of patients, fever was the next most common manifestation, seen in 62% of patients.

“Eszopiclone and lemborexant work for insomnia despite adverse events, while prescription drugs such as benzodiazepines, daridorexant, suvorexant, and trazodone can be effective but are associated with poor tolerability, according to this systematic review and meta-analysis.”

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.